Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-10T07:49:35.421Z Has data issue: false hasContentIssue false
  • English
  • Français

Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial

Published online by Cambridge University Press:  14 January 2020

Le Xiao ,
Xuequan Zhu ,
Amy Gillespie ,
Yuan Feng ,
Jingjing Zhou ,
Xu Chen ,
Yuanyuan Gao ,
Xueyi Wang ,
Xiancang Ma  and
Chengge Gao
...Show all authors
Le Xiao
Affiliation:
The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
Xuequan Zhu
Affiliation:
The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
Amy Gillespie
Affiliation:
Department of Psychiatry, University of Oxford, Oxford, UK
Yuan Feng
Affiliation:
The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
Jingjing Zhou
Affiliation:
The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
Xu Chen
Affiliation:
The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
Yuanyuan Gao
Affiliation:
Department of Psychiatry, The First Hospital of Hebei Medical University, Hebei, China
Xueyi Wang
Affiliation:
Department of Psychiatry, The First Hospital of Hebei Medical University, Hebei, China
Xiancang Ma
Affiliation:
Department of Psychiatry, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China
Chengge Gao
Affiliation:
Department of Psychiatry, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China
Yunshi Xie
Affiliation:
Department of Neurology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
Xiaoping Pan
Affiliation:
Department of Neurology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
Yan Bai
Affiliation:
Department of Psychiatry, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Xiufeng Xu
Affiliation:
Department of Psychiatry, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Gang Wang*
Affiliation:
The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China
Runsen Chen*
Affiliation:
The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China Department of Psychiatry, University of Oxford, Oxford, UK
*
Author for correspondence: Runsen Chen, E-mail: runsen.chen@psych.ox.ac.uk, Gang Wang, E-mail: gangwangdoc@vip.163.com
Author for correspondence: Runsen Chen, E-mail: runsen.chen@psych.ox.ac.uk, Gang Wang, E-mail: gangwangdoc@vip.163.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

This study aimed to examine the efficacy of combining paroxetine and mirtazapine v. switching to mirtazapine, for patients with major depressive disorder (MDD) who have had an insufficient response to SSRI monotherapy (paroxetine) after the first 2 weeks of treatment.

Methods

This double-blind, randomized, placebo-controlled, three-arm study recruited participants from five hospitals in China. Eligible participants were aged 18–60 years with MDD of at least moderate severity. Participants received paroxetine during a 2-week open-label phase and patients who had not achieved early improvement were randomized to paroxetine, mirtazapine or paroxetine combined with mirtazapine for 6 weeks. The primary outcome was improvement on the Hamilton Rating Scale for Depression 17-item (HAMD-17) scores 6 weeks after randomization.

Results

A total of 204 patients who showed early non-response to paroxetine monotherapy were randomly assigned to receive either mirtazapine and placebo (n = 68), paroxetine and placebo (n = 68) or mirtazapine and paroxetine (n = 68), with 164 patients completing the outcome assessment. At week 8, the least squares (LS) mean change of HAMD-17 scores did not significantly differ among the three groups, (12.98 points) in the mirtazapine group, (12.50 points) in the paroxetine group and (13.27 points) in the mirtazapine plus paroxetine combination group. Participants in the paroxetine monotherapy group were least likely to experience adverse effects.

Conclusions

After 8 weeks follow-up, paroxetine monotherapy, mirtazapine monotherapy and paroxetine/mirtazapine combination therapy were equally effective in non-improvers at 2 weeks. The results of this trial do not support a recommendation to routinely offer additional treatment or a switch in treatment strategies for MDD patients who do not show early improvement after 2 weeks of antidepressant treatment.

Keywords

Antidepressantearly non-responseRCTMDD
Type
Original Article
Information
Psychological Medicine , Volume 51 , Issue 7 , May 2021 , pp. 1166 - 1174
Check for updates
Copyright
Copyright © The Author(s) 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Association, A. P. (2017). Practice guideline for the treatment of patients with major depressive disorder. 2010. Washington, DC: American Psychiatric Association.Google Scholar
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., & Möller, H.-J., & Disorders, W. T. F. o. T. G. f. U. D. (2015). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: Maintenance treatment of major depressive disorder-update 2015. The World Journal of Biological Psychiatry, 16(2), 76–95.CrossRefGoogle ScholarPubMed
Blier, P., Gobbi, G., Turcotte, J. E., de Montigny, C., Boucher, N., Hébert, C., & Debonnel, G. (2009a). Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. European Neuropsychopharmacology, 19(7), 457–465.CrossRefGoogle ScholarPubMed
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2009b). Combination of antidepressant medications from treatment initiation for major depressive disorder: A double-blind randomized study. American Journal of Psychiatry, 167(3), 281–288.CrossRefGoogle ScholarPubMed
Carpenter, L. L., Yasmin, S., & Price, L. H. (2002). A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biological Psychiatry, 51(2), 183–188.CrossRefGoogle ScholarPubMed
Chen, R. (2018). Is there a role for tailoring treatment dose according to severity of symptoms? Bipolar Disorders, 20(2), 85–86.CrossRefGoogle Scholar
de Vries, Y. A., Roest, A. M., Bos, E. H., Burgerhof, J. G., van Loo, H. M., & de Jonge, P. (2019). Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: Individual patient data meta-analysis. The British Journal of Psychiatry 214(1), 4–10.CrossRefGoogle ScholarPubMed
Fang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., … Jiang, K. (2010). Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: A double-blind, randomized pilot study in a Chinese population. Journal of Clinical Psychopharmacology, 30(4), 357–364.CrossRefGoogle ScholarPubMed
Fava, M., Dunner, D. L., Greist, J. H., Preskorn, S. H., Trivedi, M. H., Zajecka, J., & Cohen, M. (2001). Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial. The Journal of Clinical Psychiatry, 62(6), 413–420.CrossRefGoogle ScholarPubMed
Galling, B., Sangroula, D., Ferrer, A. C., & Correll, C. (2016). Antidepressant augmentation and co-initiation treatment in acute major depressive disorder: A systematic review, meta-analysis and metaregression analysis. European Neuropsychopharmacology, 26, S459.CrossRefGoogle Scholar
Gelenberg, A., Freeman, M., Markowitz, J., Rosenbaum, J., Thase, M., Trivedi, M., & Van Rhoads, R. (2017). Practice guideline for the treatment of patients with major depressive disorder 2010. In.Google Scholar
Gourion, D. (2008). Antidepressants and their onset of action: A major clinical, methodological and pronostical issue. L'Encephale, 34(1), 73–81.CrossRefGoogle Scholar
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015). The economic burden of adults with major depressive disorder in the United States (2005 and 2010). The Journal of Clinical Psychiatry, 76(2), 155–162.CrossRefGoogle ScholarPubMed
Guo, T., Xiang, Y.-T., Xiao, L., Hu, C.-Q., Chiu, H. F., Ungvari, G. S., … Geng, Y. (2015). Measurement-based care versus standard care for major depression: A randomized controlled trial with blind raters. American Journal of Psychiatry, 172(10), 1004–1013.CrossRefGoogle ScholarPubMed
Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A. (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology, 29(3), 566.CrossRefGoogle ScholarPubMed
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., … MacQueen, G. M. (2016). Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. The Canadian Journal of Psychiatry, 61(9), 540–560.CrossRefGoogle Scholar
Knud, J. L. (2012). Mirtazapine versus other antidepressive agents for depression. Ugeskrift for laeger, 174(46), 2864–2866.Google Scholar
Kudlow, P. A., McIntyre, R. S., & Lam, R. W. (2014). Early switching strategies in antidepressant non-responders: Current evidence and future research directions. CNS drugs, 28(7), 601–609.CrossRefGoogle ScholarPubMed
Lam, R. W. (2012). Onset, time course and trajectories of improvement with antidepressants. European Neuropsychopharmacology, 22, S492–S498.CrossRefGoogle ScholarPubMed
Li, G., Zhang, H., Tao, l., & Huang, L. (2005). Compliance with paroxetine in the treatment of depression in primary care: a randomized comparison of initial dose 10 mg vs 20 mg. Chinese Mental Health Journal, 19(10), 715–715.Google Scholar
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., … Murray, G. (2015). Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders. Australian & New Zealand Journal of Psychiatry, 49(12), 1087–1206.CrossRefGoogle ScholarPubMed
Nakajima, S., Suzuki, T., Watanabe, K., Kashima, H., & Uchida, H. (2010). Accelerating response to antidepressant treatment in depression: A review and clinical suggestions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(2), 259–264.CrossRefGoogle ScholarPubMed
Nakajima, S., Uchida, H., Suzuki, T., Watanabe, K., Hirano, J., Yagihashi, T., … Mimura, M. (2011). Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(8), 1983–1989.CrossRefGoogle ScholarPubMed
Posternak, M. A., & Zimmerman, M. (2005). Is there a delay in the antidepressant effect? A meta-analysis. In.CrossRefGoogle Scholar
Szegedi, A., Jansen, W. T., van Willigenburg, A. P., van der Meulen, E., Stassen, H. H., & Thase, M. E. (2009). Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. The Journal of Clinical Psychiatry, 70, 344–353.CrossRefGoogle ScholarPubMed
Szegedi, A., Müller, M. J., Anghelescu, I., Klawe, C., Kohnen, R., & Benkert, O. (2003). Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. The Journal of Clinical Psychiatry, 64(4), 413–420.CrossRefGoogle ScholarPubMed
Tadić, A., Wachtlin, D., Berger, M., Braus, D. F., van Calker, D., Dahmen, N., … Helmreich, I. (2016). Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial. European Neuropsychopharmacology, 26(4), 705–716.CrossRefGoogle ScholarPubMed
Wagner, S., Engel, A., Engelmann, J., Herzog, D., Dreimüller, N., Müller, M. B., … Lieb, K. (2017). Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with major depressive disorder: Systematic review and meta-analysis. Journal of Psychiatric Research, 94, 96–106.CrossRefGoogle ScholarPubMed
Supplementary material: File

Xiao et al. supplementary material

Appendix

Download Xiao et al. supplementary material(File)
File 78 KB